# DK MedTech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/dk-medtech

- Industry: Medical Devices & Equipment
- Headquarters: Suzhou, China
- Website: www.dkmedtech.com
- Total disclosed funding: $23M
- Latest round: Series E (Jun 21, 2024)
- Investors on record: 7

## About

Based in Suzhou, China, and established in 2015, DK MedTech is a medical company that focuses on the development and production of vascular intervention medical products. It was recognized as the National High-tech Enterprise. The company has acquired 13 Class III medical device registration certificates. It also completed 5 pre-market RCT clinical studies for special-class balloons. DK MedTech has 2 branch offices in Kunshan and Nanjing. The company cooperates with Medtronic and Asahi Intecc. It acquired ISO-13485 system certification in 2017. In 2022, the company obtained 5 relevant certificates for its products. In June 2024, DK MedTech closed a series E funding.

DK MedTech's main business is the research, development, production, and sales of vascular interventional medical treatment products. Its products can be categorized into 3 series, which are cardiac intervention, peripheral intervention, and neuro intervention. The products adopt directional scoring technologies and nickel-titanium spring winding technologies. Its peripheral intervention products include peripheral balloon catheters, PTA scoring balloons, peripheral Rx balloons, etc. Products can be used in cardiovascular, cerebrovascular, peripheral vascular, and other fields.

The company generates revenue by selling vascular intervention medical products.

The company will use the series E funding for the construction of manufacturing centers and commercialization, as well as planning for overseas market investment and expansion.

## Funding rounds

- Series E, Jun 21, 2024 — Legend Capital, Qiming Venture Partners
- Series C, Dec 31, 2021 — GTJA Investment Group, Hongrun Capital
- Series B, Aug 18, 2020, $14M — Qiming Venture Partners, China Growth Capital, Jinbang Capital
- Series B, Oct 8, 2018, $8.7M — Qiming Venture Partners, Oriza Holdings

## Investors

- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series B, Series E
- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series B
- China Growth Capital (https://capitalatlas.ai/funds/china-growth-capital) — Series B
- Jinbang Capital — Series B
- GTJA Investment Group (https://capitalatlas.ai/funds/gtja-investment-group) — Series C
- Hongrun Capital — Series C
- Legend Capital — Series E